Depression screening, what the guidelines actually say

Depression screening is a case where the grade alone understates the recommendation, because the USPSTF’s Grade B here comes with a condition attached: the benefit it describes depends on what happens after a positive screen, not only on the screen itself.

What this screening is and what it looks for

Depression screening uses a brief questionnaire, commonly the PHQ-9 or a similar validated tool, to look for symptoms of major depressive disorder in people who have not already been diagnosed and show no recognized signs or symptoms on presentation. It is a case-finding tool, not a diagnostic one: a positive screen indicates that a fuller clinical evaluation is warranted, not that a diagnosis has been made. The USPSTF’s recommendation covers screening in adults generally, and separately addresses pregnant and postpartum people and older adults as populations within that same recommendation rather than as separate grades.

Who and when, per the USPSTF

The 2023 recommendation sets a single population and grade for depression itself, alongside a separate conclusion on suicide risk screening issued in the same statement:

• Adults 19 and older, including pregnant and postpartum people and older adults: Grade B. The Task Force recommends screening for depression in this population, concluding with moderate certainty that it has a moderate net benefit.
• Suicide risk screening in the same populations: Grade I. Issued in the same statement, this is a separate conclusion: the Task Force found the current evidence insufficient to weigh the balance of benefits and harms of screening specifically for suicide risk, and did not recommend for or against it.

The Task Force is explicit that the Grade B recommendation is not unconditional. Its statement says that adequate systems and clinical staff are needed to ensure that patients who are screened, and who screen positive, are accurately diagnosed and treated with evidence-based care or referred to a setting that can provide it. A screening program that asks the questions but has nowhere to send a positive result is not the program the evidence supports.

These conclusions describe who the guideline covers and the conditions the evidence rests on, not an instruction that any particular person should be screened on a particular visit or that a screening result by itself means a diagnosis. Whether and how to screen, and what happens after a positive result, is a conversation for a clinician working within a system equipped to follow through on it.

The evidence and its grade

The Task Force’s moderate-certainty, moderate-benefit conclusion is built on trials showing that screening programs, paired with adequate follow-up treatment, modestly improve outcomes for adults with depression compared with usual care, while the harms of screening itself, mainly the burden of a false positive or an unnecessary evaluation, are judged to be small. The separate insufficient-evidence conclusion on suicide risk is not a statement that suicide risk does not matter; it reflects that the trial evidence specifically testing whether screening for suicide risk, apart from depression more broadly, changes outcomes is too limited for the Task Force to reach a graded conclusion either way.

Where the guidance differs

This 2023 statement is one of two the Task Force issued the same day, and treating them as one recommendation would flatten a real distinction the Task Force drew on purpose. The companion anxiety screening recommendation, also published June 20, 2023, gives adults aged 19 to 64 a Grade B, the same letter grade depression screening carries across all adult ages, but for anxiety specifically, the Task Force found the evidence insufficient, Grade I, for adults 65 and older, citing a lack of data on screening tool accuracy and treatment effectiveness in that age group. Depression screening does not carry that same age cutoff; its Grade B extends to older adults. A page, or a clinician, that describes “the Task Force recommends screening older adults for depression and anxiety” would be correct on depression and wrong on anxiety. They are separate conditions, separate evidence reviews, and, past age 64, separate grades.

Questions to ask your clinician

Framed as questions to bring to a visit, not as steps to take on your own:

• If I screen positive for depression, what is this practice’s actual next step, evaluation, treatment, or referral, and on what timeline?
• I am pregnant or postpartum; does anything about depression screening or follow-up change for me specifically?
• I am 65 or older; the depression recommendation covers me, but I understand anxiety screening evidence is rated differently past 64. What does that distinction mean for how I am screened?
• The Task Force separately found suicide-risk screening evidence insufficient. If I have thoughts of self-harm, how should I raise that regardless of what a standard depression screen asks?
• What does a positive screening result actually tell you, and what does it not tell you, about my situation?

You can compare this profile against the full Guideline Tracker, read the sibling profile for hepatitis C screening, or see how everyday choices fit alongside screening in the big levers.